NCT03362008

Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.

A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix Tablet 1 mg and Champix® Tablet 1 mg in Healthy Adult Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, open-label, 2-way, 2-period, single-dose crossover clinical study to compare the pharmacokinetic characteristics and the safety between zeropix tablet 1 mg and champix® tablet 1 mg in healthy adult male subjects

Conditions

• Smoking, Cigarette

Interventions

Type	Name	Description
DRUG	Zeropix	administration of Zeropix
DRUG	Champix®	administration of Champix®

Timeline

• Start date: 2017-07-06
• Primary completion: 2017-07-26
• Completion: 2017-09-08
• First posted: 2017-12-05
• Last updated: 2017-12-05

Locations

1 site across 1 country: South Korea